Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 67

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 5
Chunk 67
---
 ended June 30, 2024, a decrease of A$4,239,765 or 22.7%. The decrease is attributable to the finalization of certain research and development studies during the current year.

General and administrative expenses

General and administrative expenses increased to A$5,481,399 for the year ended June 30, 2025 from A$4,762,643 for the year ended June 30, 2024, an increase of A$718,756 or 15.1%. The increase is mainly attributable to an increase in staffing costs, audit compliance expenses and consulting expenses.

Intellectual property expenses

Intellectual property expenses, which include patent portfolio costs and intellectual property related legal costs, decreased to A$127,523 for the year ended June 30, 2025 from A$214,304 for the year ended June 30, 2024, a decrease of A$86,781 or 40.5%. This decrease is mainly due to management’s efforts to reduce expenses and preserve cash.

Foreign exchange gain (loss)

We recorded a foreign exchange gain of A$259,433 for the year ended June 30, 2025 compared to a foreign exchange gain of A$261,152 for the year ended June 30, 2024. Foreign exchange gain (loss) reflects the impact of changes in foreign currency exchange rates on cash that we hold in U.S. dollars, British Pounds and Euros. In the 2025 and 2024 fiscal years, the Australian dollar slightly depreciated against the U.S. dollar, which had a favorable impact on the Australian dollar value of our cash held in U.S. dollars. In the 2025 fiscal year, we incurred a foreign exchange gain of A$255,876 attributable to the cash balances that we held in U.S. dollars, and a foreign exchange gain of A$3,557 attributable to foreign currency transactions. In the 2024 fiscal year, we incurred a foreign exchange gain of A$260,356 attributable to the cash balances that we held in U.S. dollars, and a foreign exchange gain of A$796 attributable to foreign currency transactions.

40

For a comparison of our results of operations between year ended June 30, 2024 and year ended June 2023, see Item 5.A. “Results of Operations” of our annual report on Form 20-F as filed with the SEC on September 30, 2024.

Inflation and Seasonality